2026-W46 · Nov 9–Nov 15 · Company · Profile · published
GE HealthCare Technologies Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #290 · GE 醫療公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | GEHC |
| Company | GE HealthCare Technologies Inc. |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment |
| S&P 500 rank (by weight) | #290 · 0.05% (Nov 3, 2026) |
| Sector rank | #37 in Health Care (Nov 3, 2026) |
| Headquarters | Chicago, Illinois, United States |
| Founded | 1994 |
| CEO | Peter Arduini (President and CEO) |
| Employees | ~54,000 (2025) |
| Market cap | $36.10B (Nov 3, 2026) |
| Share price | $79.41 (Nov 3, 2026) |
| SEC filings | EDGAR — CIK 0001932393 |
WHAT IT DOES
GE HealthCare Technologies is a global medical-technology and diagnostics company headquartered in Chicago, spun off from General Electric in January 2023. It supplies the imaging scanners, ultrasound systems, patient-monitoring equipment and pharmaceutical diagnostics that hospitals and clinics use to see inside the body and guide treatment.
The model is installed-base economics: a very large fleet of scanners and monitors in hospitals worldwide generates recurring service contracts, parts and software revenue alongside new equipment sales, and its Pharmaceutical Diagnostics unit sells the contrast agents consumed by those scans.
In fiscal 2025 GE HealthCare reported revenues of $20,625M, up 4.84% year over year, operating income of $2,763M and net income of $2,084M (diluted EPS $4.55), its third year as an independent company.
BUSINESS SEGMENTS
| Imaging | CT, MR, molecular imaging, X-ray, mammography and surgical imaging systems: $9,245M of fiscal 2025 revenues — the largest segment, about 45% of the total (fiscal 2025 Form 10-K). |
| Advanced Visualization Solutions | Ultrasound and image-guided therapy systems, including cardiovascular, women's health and point-of-care ultrasound: $5,354M of fiscal 2025 revenues. |
| Patient Care Solutions | Patient monitoring, anesthesia delivery, diagnostic cardiology and maternal-infant care equipment: $3,086M of fiscal 2025 revenues. |
| Pharmaceutical Diagnostics | Contrast media and molecular imaging agents used with imaging procedures: $2,900M of fiscal 2025 revenues — the group's consumables stream. |
| Other | Principally Healthcare Financial Services (equipment financing): about $40M of fiscal 2025 revenues (residual of reported segment revenues versus the group total). |
HISTORY
| Year | Milestone |
|---|---|
| 1994 | GE's medical systems business organized as the healthcare subsidiary that became GE Healthcare (roots run to early X-ray pioneers). |
| 2004 | GE completed the acquisition of Amersham plc (about $9.5B), adding life sciences and the diagnostics/media business that anchors Pharmaceutical Diagnostics. |
| 2022 | GE HealthCare Technologies Inc. formed as the spin-off vehicle (May 16, 2022) as GE prepared its three-way breakup. |
| 2023 | Spin-off from GE completed (January 2023); GE HealthCare began trading on Nasdaq and joined the S&P 500. |
| 2025 | Third year as an independent company: revenues rose 4.84% to $20,625M with net income of $2,084M. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $20.63B — FY2025 total revenues, +4.84% year over year |
| Operating income | $2,763M — FY2025 operating income (EBIT) |
| Net income attributable to GE HealthCare | $2,084M — FY2025 net income attributable to GE HealthCare |
| Diluted EPS | $4.55 — FY2025 diluted EPS |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
GE HealthCare is #290 in the S&P 500 with a 0.05% weight (Nov 3, 2026) and #37 of 60 in Health Care by market cap; at $36.10B it is the index's principal pure-play medical-imaging equipment name — a 2023 spin-off carrying a century-scale installed base, and one of the clearest index proxies for global hospital capital spending.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | GE HealthCare fiscal 2025 Form 10-K compilation via StockAnalysis; company site and Wikipedia for identity (retrieved Nov 3, 2026) |
| Index weight & ranks | Slickcharts S&P 500 weights and market caps, fetched Nov 3, 2026 (fresh snapshot for this batch) |
| Market cap | $36.10B (Nov 3, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | GEHC |
| 公司 | GE HealthCare Technologies Inc.(GE 醫療) |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健設備 |
| 標普500排名(按權重) | #290 · 0.05%(Nov 3, 2026) |
| 板塊內排名 | 醫療保健 #37(Nov 3, 2026) |
| 總部 | 美國伊利諾伊州芝加哥 |
| 成立 | 1994年 |
| 執行長 | Peter Arduini(總裁兼執行長) |
| 員工 | 約54,000(2025年) |
| 市值 | $36.10B(Nov 3, 2026) |
| 股價 | $79.41(Nov 3, 2026) |
| SEC 申報 | EDGAR — CIK 0001932393 |
業務概覽
GE HealthCare Technologies 是總部位於芝加哥的全球醫療科技與診斷公司,2023 年 1 月自通用電氣分拆獨立。它供應醫院與診所用以透視人體、引導治療的影像掃描儀、超聲波系統、病人監護設備及藥物診斷產品。
其模式是裝機量經濟:遍佈全球醫院的大量掃描儀與監護設備,在新設備銷售之外帶來經常性的服務合約、零件與軟件收入;藥物診斷部門則銷售掃描所消耗的造影劑。
2025 財年 GE HealthCare 收入 206.25 億美元、按年增長 4.84%,營業利潤 27.63 億美元、淨利潤 20.84 億美元(稀釋每股盈利 4.55 美元),為獨立營運第三年。
業務板塊
| 影像 | CT、MR、分子影像、X 光、乳房造影及手術影像系統:2025 財年收入 92.45 億美元,是最大板塊,約佔總額 45%(2025 財年 Form 10-K)。 |
| 先進可視化解決方案 | 超聲波及影像引導治療系統,包括心血管、婦女健康與床邊超聲波:2025 財年收入 53.54 億美元。 |
| 病人護理解決方案 | 病人監護、麻醉輸送、診斷心臟學及母嬰護理設備:2025 財年收入 30.86 億美元。 |
| 藥物診斷 | 影像檢查所用的造影劑及分子影像藥劑:2025 財年收入 29.00 億美元,是集團的耗材收入來源。 |
| 其他 | 主要為醫療金融服務(設備融資):2025 財年收入約 0.40 億美元(已列報板塊收入與集團總額的差額)。 |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1994 | GE 的醫療系統業務組建為後來的 GE Healthcare 子公司(源流可溯至早期 X 光先驅)。 |
| 2004 | GE 完成收購 Amersham plc(約 95 億美元),加入生命科學及診斷/造影劑業務,成為今日藥物診斷板塊的根基。 |
| 2022 | GE HealthCare Technologies Inc. 成立為分拆載體(2022 年 5 月 16 日),配合 GE 的三分拆計劃。 |
| 2023 | 自 GE 的分拆完成(2023 年 1 月);GE HealthCare 於 Nasdaq 掛牌並加入標普500。 |
| 2025 | 獨立營運第三年:收入增長 4.84% 至 206.25 億美元,淨利潤 20.84 億美元。 |
競爭地位
財務快照
| 總收入 | 206.3 億美元 — 2025 財年總收入,按年增長 4.84% |
| 營業利潤 | 27.63 億美元 — 2025 財年營業利潤(EBIT) |
| 歸屬於 GE HealthCare 的淨利潤 | 20.84 億美元 — 2025 財年歸屬於 GE HealthCare 的淨利潤 |
| 稀釋每股盈利 | 4.55 美元 — 2025 財年稀釋每股盈利 |
主要風險
對標普500的重要性
GE HealthCare 在標普500排名 #290、權重 0.05%(2026 年 11 月 3 日),在醫療保健板塊以市值計排第 37(共 60 家);市值 361.0 億美元,是指數內主要的純醫療影像設備股——一間 2023 年分拆、承載逾百年裝機基礎的公司,也是環球醫院資本開支最清晰的指數指標之一。
來源與方法
| 財務、板塊、總部 | GE HealthCare 2025 財年 Form 10-K 整理(經 StockAnalysis);公司官網及維基百科核對公司身份(2026 年 11 月 3 日讀取) |
| 指數權重與排名 | Slickcharts 標普500權重與市值,2026 年 11 月 3 日抓取(本批新鮮快照) |
| 市值 | $36.10B(Nov 3, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
月線共 45 根,2023 年 1 月至 2026 年 9 月(2023 年 1 月自 GE 分拆後於 Nasdaq 上市)。首根(2023 年 1 月)收市 $69.52;2026 年 9 月:開市 $71.25、高 $71.88、低 $62.99、收市 $65.37。期內高位 $94.80(2025 年 2 月);期內低位 $53.50(2023 年 1 月)。
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 10:34 · updated 2026-11-14 23:26 · rev 8